Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The intestine is one of the first affected organs in Parkinson's disease (PD). PD subjects show abnormal staining for Escherichia coli and α-synuclein in the colon. METHODS: We recruited 52 PD patients and 36 healthy cohabitants. We measured serum markers and quantified the numbers of 19 fecal bacterial groups/genera/species by quantitative RT-PCR of 16S or 23S rRNA. Although the six most predominant bacterial groups/genera/species covered on average 71.3% of total intestinal bacteria, our analysis was not comprehensive compared to metagenome analysis or 16S rRNA amplicon sequencing. RESULTS: In PD, the number of Lactobacillus was higher, while the sum of analyzed bacteria, Clostridium coccoides group, and Bacteroides fragilis group were lower than controls. Additionally, the sum of putative hydrogen-producing bacteria was lower in PD. A linear regression model to predict disease durations demonstrated that C. coccoides group and Lactobacillus gasseri subgroup had the largest negative and positive coefficients, respectively. As a linear regression model to predict stool frequencies showed that these bacteria were not associated with constipation, changes in these bacteria were unlikely to represent worsening of constipation in the course of progression of PD. In PD, the serum lipopolysaccharide (LPS)-binding protein levels were lower than controls, while the levels of serum diamine oxidase, a marker for intestinal mucosal integrity, remained unchanged in PD. CONCLUSIONS: The permeability to LPS is likely to be increased without compromising the integrity of intestinal mucosa in PD. The increased intestinal permeability in PD may make the patients susceptible to intestinal dysbiosis. Conversely, intestinal dysbiosis may lead to the increased intestinal permeability. One or both of the two mechanisms may be operational in development and progression of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with most of the diseases, PD patients have a different microbiota composition compared to healthy controls or patients affected by other neurological disorders (174–176).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [174]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A clinical study revealed that the level of serum LPS-binding protein in patients with Parkinson's disease was lower than that in controls, indicating that increased intestinal permeability and increased invasion of Gram-negative bacteria leads to an increase in LPS in the circulatory system.148”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“serum from PD patients contains low levels of LPS binding protein [145,146], which are indicative of a chronic systemic exposure to LPS and gram negative endobacteria [147,148,149]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [145]
In the citing paper
“Reduced number of Prevotella may be associated with decreased mucin synthesis causing increased gut permeability [413].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [413]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Postmortem studies of non-PD subjects disclosed incidental α-synuclein-positive Lewy bodies in the gastrointestinal tract, the olfactory system, and the cardiac sympathetic system, which suggests that α-synuclein pathology in PD may start in these tissues [2].”
BackgroundDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
(2023) · doi:10.1126/science · Cited by 6,063
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 2×
“Direct evidence supporting the notion that intestinal microbiota determines a clinical phenotype has been recently reported in obesity [9].”
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472 · cited 1×
“PD is predicted to affect more than 10 million people worldwide by the year 2030 [1].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“In contrast to Prevotella, the count of Lactobacillus was increased 22-fold in the previous report [10], and 6.”
BackgroundResultOccurrence, Classification, and Biological Function of Hydrogenases: An Overview
Vignais, P. M., & Billoud, B. (2007) · Chemical Reviews · doi:10.1021/cr050196r · Cited by 1,578 · cited 1×
“According to an extensive review of bacterial hydrogenases [25], B.”
BackgroundDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“Intestinal microbiota in PD was recently published [10, 11].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 4×
“In PD, intestinal permeability is increased and the hyperpermeability is correlated with increased intestinal staining for Escherichia coli; nitrotyrosine, a marker for protein oxidation; and α-synuclein [7].”
BackgroundResultInfluential
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
“Conversely, the gut microbiomes in human subjects with PD contain an increased abundance of Proteobacteria (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016), remarkably similar to our results in mice.”
InfluentialThe gut microbiota–brain axis in behaviour and brain disorders
Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00460-0 · Cited by 2,149
The central nervous system and the gut microbiome
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513
“Concurrently, individuals afflicted with Parkinson’s disease (PD) display significantly different fecal and mucosal microbial populations (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015).”
BackgroundCattaneo, A., Cattane, N., Galluzzi, S., Provasi, S., Lopizzo, N., Festari, C., Ferrari, C., Guerra, U. P., Paghera, B., Muscio, C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.019 · Cited by 1,382
“Two interesting studies (Keshavarzian et al., 2015; Hasegawa et al., 2015) provide evidence that pro-inflammatory dysbiosis could trigger inflammation-induced misfolding of α -synuclein the development of PD.”
BackgroundThe gut microbiome in neurological disorders
Cryan, J. F., O'Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30356-4 · Cited by 1,336
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development
Ghosh, S. S., Wang, J., Yannie, P. J., & Ghosh, S. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz039 · Cited by 759
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
“A number of reports now indicate that PD patients have increased intestinal permeability compared to healthy controls.(39,73,81,85,86) The results obtained from several of these studies specifically indicate defects in intestinal tight junctions without gross mucosal damage, including reductions in levels of barrier-p…”
ResultHeintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554
The gut microbiome in human neurological disease: A review
Tremlett, H., Bauer, K. C., Appel‐Cresswell, S., Finlay, B. B., & Waubant, E. (2017) · Annals of Neurology · doi:10.1002/ana.24901 · Cited by 535
“Finally, a Japanese study reported counts of 19 previously cultured microbial groups in stool samples from PD cases and spousal controls.(95) Lower bacterial counts were observed in PD cases relative to controls, as were lower serum levels of lipopolysaccharide-binding protein.”
BackgroundResultInfluentialAnalysis of Gut Microbiota in Patients with Parkinson’s Disease
Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y. B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., et al. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3700-7 · Cited by 487
Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
Lin, C.-H., Chen, C.-C., Chiang, H.-L., Liou, J.-M., Chang, C.-M., Lu, T.-P., Chuang, E. Y., Tai, Y.-C., Cheng, C., Lin, H.-Y., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1528-y · Cited by 469
Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., Voigt, R. M., Naqib, A., Green, S. J., Kordower, J. H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316844 · Cited by 467
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice
Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., et al. (2020) · eLife · doi:10.7554/elife.53111 · Cited by 439
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Microbiota-Gut-Brain Axis: New Therapeutic Opportunities
Long-Smith, C., O'Riordan, K. J., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023628 · Cited by 419
Fecal Microbiota Transplantation in Neurological Disorders
Vendrik, K. E. W., Ooijevaar, R. E., de Jong, P. R. C., Laman, J. D., van Oosten, B. W., van Hilten, J. J., Ducarmon, Q. R., Keller, J. J., Kuijper, E. J., & Contarino, M. F. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00098 · Cited by 413
“A different human gut microbiota composition compared to healthy controls has been reported for several neurological disorders, such as Parkinson’s disease (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016), multiple sclerosis (Miyake et al.”
BackgroundAlteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409
The role of microbial amyloid in neurodegeneration
Friedland, R. P., & Chapman, M. R. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006654 · Cited by 391
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393
“Consistently with previous studies (Supplementary Table 1), we observed a decrease in taxa belonging to Firmicutes pylum, such as the Lachnospiraceae family and other genera (eg, Roseburia)(10,13,15,20,21,23) and an increase in Verrucomicrobia,(9,10,13,15,19) Proteobacteria,(10,13,21,23,50) Christensenellaceae,(15,20)…”
ResultMeta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370
“First, intestinal permeability is increased in PD.(26,27) Second, expression of the tight junction protein, occludin, is decreased in PD.”
BackgroundSelf-citationGut–organ axis: a microbial outreach and networking
Ahlawat, S., Asha, & Sharma, K. K. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13333 · Cited by 361
“Parkinson’s disease 52 PD patients/36 healthy controls ↑ Lactobacillus ↓ Clostridium coccoides, C. leptum and Bacteroides fragilis Quantitative RT-PCR of 16S or 23S rRNA Due to dybiosis worsening of constipation leads to progression of PD Hasegawa et al. (2015) 8.”
BackgroundThe Association between Early-Life Gut Microbiota and Long-Term Health and Diseases
Sarkar, A., Yoo, J. Y., Valeria Ozorio Dutra, S., Morgan, K. H., & Groer, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030459 · Cited by 342
“Compared to 36 cohabiting healthy controls, 52 PD patients had more lactobacillus, fewer hydrogen-producing bacteria, and lower serum lipopolysaccharide (LPS)binding protein levels [180].”
BackgroundGut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Hamamah, S., Aghazarian, A., Nazaryan, A., Hajnal, A., & Covasa, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020436 · Cited by 307
Yamashiro, K., Tanaka, R., Urabe, T., Ueno, Y., Yamashiro, Y., Nomoto, K., Takahashi, T., Tsuji, H., Asahara, T., & Hattori, N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171521 · Cited by 314
Self-citationGut microbiota in Parkinson disease in a northern German cohort
Hopfner, F., Künstner, A., Müller, S. H., Künzel, S., Zeuner, K. E., Margraf, N. G., Deuschl, G., Baines, J. F., & Kuhlenbäumer, G. (2017) · Brain Research · doi:10.1016/j.brainres.2017.04.019 · Cited by 318
The role of lipopolysaccharide-induced cell signalling in chronic inflammation
Page, M. J., Kell, D. B., & Pretorius, E. (2022) · Chronic Stress · doi:10.1177/24705470221076390 · Cited by 315
Changes of colonic bacterial composition in Parkinson's disease and other neurodegenerative diseases
Gerhardt, S., & Mohajeri, M. H. (2018) · Nutrients · doi:10.3390/nu10060708 · Cited by 298
Gut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease
Vascellari, S., Palmas, V., Melis, M., Pisanu, S., Cusano, R., Uva, P., Perra, D., Madau, V., Sarchioto, M., Oppo, V., et al. (2020) · mSystems · doi:10.1128/msystems.00561-20 · Cited by 286
The gut microbiota–brain axis in neurological disorder
Ullah, H., Arbab, S., Tian, Y., Liu, C.-Q., Chen, Y., Qijie, L., Khan, M. I. U., Hassan, I. U., & Li, K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1225875 · Cited by 255
“Despite people with other diseases, people with PD have a different microbiome composition from people who are healthy or have other neurological disorders (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015).”
BackgroundThe role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Biomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270
“Others reported that PD patients displayed an increased abundance of Akkermansia, Lactobacillus, Bifidobacterium and Flavonifractor, along with a decrease in SCFA-producing bacteria, including Lachnospiraceae [41, 42, 84, 98].”
BackgroundUnhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.005 · Cited by 266
“However, not all experts agree that the association between the microbial dysbiosis and PD is related to the compromised integrity of the intestinal mucosa (Hasegawa et al., 2015).”
Wallen, Z. D., Appah, M., Dean, M. N., Sesler, C. L., Factor, S. A., Molho, E., Zabetian, C. P., Standaert, D. G., & Payami, H. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-0112-6 · Cited by 252
Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study
Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187307 · Cited by 248
Self-citationThe role of the microbiota-gut-brain axis in neuropsychiatric disorders
Generoso, J. S., Giridharan, V. V., Lee, J., Macedo, D., & Barichello, T. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0987 · Cited by 211
The intestinal barrier in disorders of the central nervous system
Pellegrini, C., Fornai, M., D'Antongiovanni, V., Antonioli, L., Bernardini, N., & Derkinderen, P. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00241-2 · Cited by 239
α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease
Chandra, R., Hiniker, A., Kuo, Y.-M., Nussbaum, R. L., & Liddle, R. A. (2017) · JCI Insight · doi:10.1172/jci.insight.92295 · Cited by 236
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Baldini, F., Hertel, J., Sandt, E., Thinnes, C. C., Neuberger-Castillo, L., Pavelka, L., Betsou, F., Krüger, R., Thiele, I., on behalf of the NCER-PD Consortium, et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00775-7 · Cited by 230
Parkinson’s disease from the gut
Liddle, R. A. (2018) · Brain Research · doi:10.1016/j.brainres.2018.01.010 · Cited by 219
The Microbiome as a Modifier of Neurodegenerative Disease Risk
Fang, P., Kazmi, S. A., Jameson, K. G., & Hsiao, E. Y. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.008 · Cited by 226
“Clinical studies profiling the microbiota of PD patients reported many alterations relative to healthy controls, including increases in the relative abundance of Bifidobacterium (Hasegawa et al., 2015; Peng et al., 2018), Lactobacillus (Hasegawa et al.”
BackgroundInfluentialComprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry
Shao, Y., Li, T., Liu, Z., Wang, X., Xu, X., Li, S., Xu, G., & Le, W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00425-8 · Cited by 226
“Besides, alterations of several other Clostridium species and Bacteroides species that involved in tryptophan catabolism were also observed in PD [54, 67].”
BackgroundThe function of gut microbiota in immune-related neurological disorders: a review
Sittipo, P., Choi, J., Lee, S., & Lee, Y. K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02510-1 · Cited by 221
“The level of Clostridium coccidias was found to be increased in early PD, whereas Lactobacillus gassier was increased in advanced PD [175].”
BackgroundGut bacterial profiles in Parkinson's disease: A systematic review
Li, Z., Liang, H., Hu, Y., Lu, L., Zheng, C., Fan, Y., Wu, B., Zou, T., Luo, X., Zhang, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13990 · Cited by 206
Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder
Nguyen, T. T., Kosciolek, T., Eyler, L. T., Knight, R., & Jeste, D. V. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.01.013 · Cited by 205
“On the other end of the developmental spectrum, patients with Parkinson's disease (PD) display altered microbiomes (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015), and the microbiome has been shown to promote progression to PD in genetically susceptible individuals.”
The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease
Tran, S. M.-S., & Mohajeri, M. H. (2021) · Nutrients · doi:10.3390/nu13030732 · Cited by 210
Microbiota Signaling Pathways that Influence Neurologic Disease
Cox, L. M., & Weiner, H. L. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0598-8 · Cited by 207
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease
Houser, M. C., Chang, J., Factor, S. A., Molho, E. S., Zabetian, C. P., Hill‐Burns, E. M., Payami, H., Hertzberg, V. S., & Tansey, M. G. (2018) · Movement Disorders · doi:10.1002/mds.27326 · Cited by 199
Long-Term Cognitive Dysfunction in Cancer Survivors
Országhová, Z., Mego, M., & Chovanec, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.770413 · Cited by 176
“Differences in the gut microbiome have been observed in Alzheimer’s disease, Parkinson’s disease and autism spectrum disorders (Hasegawa et al., 2015; Zhang et al., 2017; Sharon et al., 2019).”
BackgroundImmune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 178
“With regard to peripheral organs, several groups have reported alterations in the gut microbiome of PD patients (Hasegawa et al., 2015; Hill- Burns et al., 2017; Keshavarzian et al., 2015; Petrov et al., 2017; Scheperjans et al., 2015; Unger et al., 2016), which may be related to the effects of diets, infections, or g…”
BackgroundOutside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Does Parkinson’s disease start in the gut?
Lionnet, A., Leclair-Visonneau, L., Neunlist, M., Murayama, S., Takao, M., Adler, C. H., Derkinderen, P., & Beach, T. G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1777-8 · Cited by 176
“Evidence for the gut as a possible initial site of PD pathology and the observation of epithelial intestinal dysfunction in PD subjects provided the framework for 5 recent studies on the gut microbiota in PD [28, 29, 40, 68, 80].”
BackgroundResultBoertien, J. M., Pereira, P. A. B., Aho, V. T. E., & Scheperjans, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191711 · Cited by 170
Gut Microbiota Differs Between Parkinson’s Disease Patients and Healthy Controls in Northeast China
Li, C., Cui, L., Yang, Y., Miao, J., Zhao, X., Zhang, J., Cui, G., & Zhang, Y. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00171 · Cited by 178
“Recruiting the spouses of PD patients as controls could also help offsetting the potential impact on gut microbiota by the physical and socioeconomic stress that is present in both PD patients and their spouses (O’Reilly et al., 1996; Hemmerle et al., 2012; Anderson et al., 2016).”
BackgroundGut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
“found that plasma level of the LPS-binding protein was decreased in PD patients (101), suggesting more LPS reaches the CNS.”
BackgroundYang, X., Qian, Y., Xu, S., Song, Y., & Xiao, Q. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00441 · Cited by 173
“When looking at the correlations, the genus of Lactobacillus was inversely correlated with gastrointestinal and motor functions, the genus of Desulfovibrio was positively correlated with gastrointestinal and motor functions.”
ResultInfluentialParkinson’s Disease and the Gastrointestinal Microbiome
Lubomski, M., Tan, A. H., Lim, S.-Y., Holmes, A. J., Davis, R. L., & Sue, C. M. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09320-1 · Cited by 172
“Evidence suggests that increased levels of Escherichia coli [62] and the proteobacteria Ralstonia [69], as well as lower plasma lipopolysaccharide-binding protein [70], reflect higher endotoxin exposure and drive intestinal inflammation.”
BackgroundInfluentialRole of Endogenous Lipopolysaccharides in Neurological Disorders
Kalyan, M., Hediyal, T. A., Sonali, S., Vichitra, C., Sunanda, T., Praveenraj, S. S., Ray, B., Gorantla, V. R., Rungratanawanich, W., Mahalakshmi, A. M., et al. (2022) · Cells · doi:10.3390/cells11244038 · Cited by 185
“Metagenome analysis or 16S rRNA amplicon sequencing showed increased relative abundance of Lactobacillus, whilst the absolute counts of the Clostridium coccoides group, the Bacteroides fragilis group, and the putative hydrogen-producing bacteria Prevotella [90,91] were decreased in PD subjects compared to those of hea…”
BackgroundAutoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells
Garretti, F., Agalliu, D., Lindestam Arlehamn, C. S., Sette, A., & Sulzer, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00303 · Cited by 162
“Clinical studies have revealed altered gut microbiota composition in PD patients that may either increase inflammation (12, 13) or gut permeability (14, 15).”
BackgroundNagpal, R., Tsuji, H., Takahashi, T., Nomoto, K., Kawashima, K., Nagata, S., & Yamashiro, Y. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01388 · Cited by 152
“…although we have previously validated that the sum of the fecal counts of all the bacterial groups enumerated herein using RT-qPCR assays correspond to 71.3 ± 9.4% (mean ± SD) of total intestinal bacterial count as estimated by in situ hybridization using a universal probe (Hasegawa et al., 2015).”
MethodSelf-citationThe Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Nair, A. T., Ramachandran, V., Joghee, N. M., Antony, S., & Ramalingam, G. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17105 · Cited by 155
Implications of the Gut Microbiome in Parkinson's Disease
Elfil, M., Kamel, S., Kandil, M., Koo, B. B., & Schaefer, S. M. (2020) · Movement Disorders · doi:10.1002/mds.28004 · Cited by 151
Implications of Gut Microbiota in Neurodegenerative Diseases
Zhang, H., Chen, Y., Wang, Z., Xie, G., Liu, M., Yuan, B., Chai, H., Wang, W., & Cheng, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.785644 · Cited by 177
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
Parkinson’s Disease and Gut Microbiota
Hirayama, M., & Ohno, K. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518147 · Cited by 158
Self-citationLi, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
“Furthermore, an increase in LPS level and a decrease in LPS binding protein level were found in the blood and plasma of PD patients, which indicated that immune cells and peripheral tissues were more exposed to LPS (de Waal et al. 2018; Hasegawa et al. 2015).”
BackgroundProbiotics for Parkinson’s Disease
Gazerani, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174121 · Cited by 151
“Lactobacillus ↑, Clostridium coccoides ↓, Bacteroides fragilis ↓, [93] Prevotella (hydrogen sulfide producer) ↓ Ralstonia ↑, Blautia ↓, Coprococcus ↓, Faecalibacterium ↓, Roseburia ↓, [52] Enterobacteriaceae ↑, Prevotellaceae ↓ [92]”
BackgroundJiang, Y., Li, K., Li, X., Xu, L., & Yang, Z. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109452 · Cited by 154
Dutta, S. K., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 149
“The Clostridium coccoides species was found to be high in patients with early PD, while Lactobacillus gasseri has been reported to be high in patients with advanced PD.(89) As PD advances clinically, there is dysfunction of ENS (dysautonomia) which leads to greater slowing of GI motility, which in turn predisposes PD…”
BackgroundEicher, T. P., & Mohajeri, M. H. (2022) · Nutrients · doi:10.3390/nu14132661 · Cited by 142
Biomarker Research in Parkinson’s Disease Using Metabolite Profiling
Havelund, J., Heegaard, N., Færgeman, N., & Gramsbergen, J. (2017) · Metabolites · doi:10.3390/metabo7030042 · Cited by 145
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
“Briefly these include PD subjects to exhibit: increased relative abundance of genera Akkermansia (7 studies) (98, 105, 108– 112), Bifidobacterium (5 studies) (103, 108, 110, 113, 114), and Lactobacillus (7 studies) (97, 103, 110, 111, 113, 115, 116); decreased abundance of genus Prevotella (7 studies) (97, 103, 104, 1…”
BackgroundInflammatory bowel diseases and Parkinson's disease
Brudek, T. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191729 · Cited by 139
“PD mice show a strong immune response in the gut [95], and colonic biopsies of PD patients show evidence of a structural dysfunction of the intestinal barrier, reinforcing the idea of a role of the GI tract in the initiation and/or the progression of the disease [96, 97].”
BackgroundGut Metagenomics-Derived Genes as Potential Biomarkers of Parkinson’s Disease
Qian, Y., Yang, X., Xu, S., Huang, P., Li, B., Du, J., He, Y., Su, B., Xu, L.-M., Wang, L., et al. (2020) · Brain · doi:10.1093/brain/awaa201 · Cited by 139
Bicknell, B. T., Liebert, A. D., Borody, T. J., Herkes, G., McLachlan, C. S., & Kiat, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119577 · Cited by 147
Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · mSystems · doi:10.1128/msystems.00797-20 · Cited by 133
“Indeed, intestinal permeability is increased in PD (70), and the serum lipopolysaccharide-binding protein levels are decreased in PD (31, 70).”
BackgroundSelf-citationThe Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Spichak, S., Bastiaanssen, T. F. S., Berding, K., Vlckova, K., Clarke, G., Dinan, T. G., & Cryan, J. F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.044 · Cited by 127
Infection and Risk of Parkinson’s Disease
Smeyne, R. J., Noyce, A. J., Byrne, M., Savica, R., & Marras, C. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202279 · Cited by 125
“A recent study reported that there was a dysbiotic alteration of the microbiotic bacteria in PD in the families of Bifidobacteriaceae, Christensenellaceae, Lachnospiraceae, Lactobacillaceae, Pasteurellaceae and Verrucomicrobiaceae [67].”
BackgroundHall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36497-x · Cited by 124
Johnson, M. E., Stringer, A., & Bobrovskaya, L. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.02.013 · Cited by 122
Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis
Bullich, C., Keshavarzian, A., Garssen, J., Kraneveld, A., & Perez‐Pardo, P. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12840 · Cited by 114
“It should be noted that these studies were conducted in different parts of the United States,52,55 Europe (including Western51,54,57,58,60,63 and Eastern Europe56), and Asia.53,59,61,62 All studies found abnormal microbiota composition in PD compared to controls.”
BackgroundMethodResultInfluentialThe Gut-Brain Axis: Two Ways Signaling in Parkinson’s Disease
Dogra, N., Mani, R. J., & Katare, D. P. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01066-7 · Cited by 133
Hegelmaier, T., Lebbing, M., Duscha, A., Tomaske, L., Tönges, L., Holm, J. B., Bjørn Nielsen, H., Gatermann, S. G., Przuntek, H., & Haghikia, A. (2020) · Cells · doi:10.3390/cells9020376 · Cited by 118
Nishiwaki, H., Ito, M., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Yoshida, T., Hanada, H., Takeuchi, I., et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00328-5 · Cited by 116
Self-citationGut Microbiota Composition Before and After Use of Proton Pump Inhibitors
Hojo, M., Asahara, T., Nagahara, A., Takeda, T., Matsumoto, K., Ueyama, H., Matsumoto, K., Asaoka, D., Takahashi, T., Nomoto, K., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5122-4 · Cited by 114
“In addition to our results, increased numbers of Lactobacillus were also observed in patients with diseases such as diabetes mellitus type 2 [36] and Parkinson’s disease [57].”
Self-citationThe Search for Environmental Causes of Parkinson’s Disease: Moving Forward
Chen, H., & Ritz, B. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181493 · Cited by 107
Invited Review: From nose to gut – the role of the microbiome in neurological disease
Bell, J. S., Spencer, J. I., Yates, R. L., Yee, S. A., Jacobs, B. M., & DeLuca, G. C. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12520 · Cited by 110
Mulak, A., Koszewicz, M., Panek-Jeziorna, M., Koziorowska-Gawron, E., & Budrewicz, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00992 · Cited by 110
“Accumulating data confirm that both qualitative and quantitative alterations in the gut microbiota composition may precede or occur during the course of PD (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Sampson et al., 2016; Unger et al., 2016; Bedarf et al., 2017; Hill-Burns et al., 2017…”
BackgroundGhosh, S. S., He, H., Wang, J., Gehr, T. W., & Ghosh, S. (2018) · Tissue Barriers · doi:10.1080/21688370.2018.1425085 · Cited by 106
“Increased intestinal permeability with high levels of circulating LPS and low levels of LPS binding protein are also seen in patients with Parkinson’s disease.(81) Abnormal intestinal permeability similarly plays a critical role in the pathogenesis of several autoimmune diseases.”
Background
Metadata
- Authors
- Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Yakult Central Institute (JP)
- Aichi University of Education (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-05
- Volume
- 10
- Issue
- 11
- Pages
- e0142164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4634857
- OpenAlex
- W2097335121
- Cited by
- 523
- References
- 51
- Citations by year
- 2026: 28 · 2025: 38 · 2024: 51 · 2023: 79 · 2022: 70 · 2021: 80 · 2020: 57 · 2019: 41 · 2018: 51 · 2017: 22 · 2016: 6
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science (15K09350, 25870317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, lipopolysaccharide-binding protein, intestinal permeability, Lactobacillus, Clostridium coccoides, Bacteroides fragilis, hydrogen-producing bacteria, Lactobacillus gasseri, constipation, diamine oxidase, intestinal mucosal integrity, fecal microbiota, disease progression
- MeSH terms
- Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Bacteria, Carrier Proteins, Constipation, DNA, Bacterial, Feces, Female, Humans, Intestinal Mucosa, Male, Membrane Glycoproteins, Parkinson Disease, Permeability, RNA, Ribosomal, 16S, Case-Control Studies, Metagenome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.